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Abstract—Cardiac hypertrophy is often associated with an increased sympathetic drive, and both in vitro and in vivo
studies have demonstrated the development of cardiomyocyte hypertrophy in response to either a- or b-adrenergic
stimulation. Because an association between the Na1/H1 exchanger and cellular growth has been proposed, this study
aimed to analyze the possible role of the antiporter in isoproterenol-induced cardiac hypertrophy. Isoproterenol alone
(5 mg/kg IP once daily) or combined with a selective inhibitor of the Na1/H1 exchanger activity (3 mg · kg21 · d21
BIIB723) was given to male Wistar rats for 30 days. Sex- and age-matched rats that received 0.9% saline IP daily served
as controls. Echocardiographic follow-up showed a 33% increase in left ventricular mass in the isoproterenol-treated
group, whereas it did not increase in the isoproterenol1BIIB723-treated group. Heart weight–to–body weight ratio at
necropsy was 2.4460.11 in controls and increased to 3.3560.10 (P,0.05) with isoproterenol, an effect that was
markedly attenuated by BIIB723 (2.8260.07). Intense cardiomyocyte enlargement and severe subendocardial fibrosis
were found in isoproterenol-treated rats, and both effects were attenuated by BIIB723. Myocardial Na1/H1 exchanger
activity and protein expression significantly increased in isoproterenol-treated rats compared with the control group
(1.4560.11 vs 0.9160.05 arbitrary units, P,0.05). This effect was significantly reduced by BIIB723 (1.1760.02,
P,0.05). In conclusion, our results show that Na1/H1 exchanger inhibition prevented the development of isoproterenol-
induced hypertrophy and fibrosis, providing strong evidence in favor of a key role played by the antiporter in this model
of cardiac hypertrophy. (Hypertension. 2003;41:1324-1329.)
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Increased sympathetic activity is often implicated in thedevelopment of cardiac hypertrophy (CH). A correlation
between cardiac mass and sympathetic activity was found in
young hypertensive humans,1 and long-term infusion of
subpressor doses of norepinephrine leads to CH in dogs and
rats.2,3 This cardiotrophic effect of catecholamines involves
both a- or b-adrenergic receptors.4 It is well recognized that
repeated or continuous injections of the b-adrenoceptor
agonist isoproterenol (Iso) causes, within days, clear CH,5
and therefore it represents a useful experimental model.
Although several mechanisms have been imputed to un-
derlie the cardiotrophic action of Iso,5–7 the exact nature is
still under debate. Because cumulative evidence supports a
cause-effect link between the activity of the Na1/H1 ex-
changer (NHE) and cardiac cell growth (Cingolani and
Camilión de Hurtado8), we sought to analyze the possible role
of NHE activity in Iso-induced CH by taking advantage of the
specific, orally active inhibitor against NHE isoform 1
(NHE-1). This study provides evidence indicating a key role
for NHE-1 activity as a mechanism underlying the develop-
ment of CH and fibrosis induced by Iso.
Methods
The investigation was performed in accordance with the Guide for
the Care and Use of Laboratory Animals (NIH publication No.
85-23, revised 1996). Male 16- to 18-week-old Wistar rats with free
access to standard rat chow and tap water were randomly assigned to
1 of the following groups: (1) control (Ctrl, n510), which received
a daily injection of 0.9% saline IP; (2) Iso (n512), which received
5.0 mg/kg (6)isoproterenol hydrochloride (Sigma) dissolved in 0.3
mL saline IP once daily,9 and (3) Iso1BIIB (n58), which received
3.0 mg · kg21 · d21 BIIB723 (Boehringer-Ingelheim) in the drinking
water plus the daily injection of Iso. The solution of BIIB723 was
prepared every day according to the daily records of water consump-
tion and body weight (BW), the latter measured every 2 days.
Systolic blood pressure, by the indirect tail-cuff method, and heart
rate were determined weekly during treatment, which lasted 30 days.
At the end of treatment, animals were euthanized under deep ether
anesthesia, and the hearts removed and subjected to further analysis.
The ventricles were blotted and weighed (HW), and HW normalized
by BW (HW/BW ratio, in mg/g) was used as a hypertrophy index.
Only 1 rat, from the Iso-treated group, died during the protocol.
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Measurement of pHi
One papillary muscle isolated from the left ventricle (LV) of each heart,
isometrically contracting at 0.2 Hz, was used for pHi determinations
with the epifluorescence approach (BCECF) previously detailed.10
Echocardiographic Examination
Rats were monitored echocardiographically under light anesthesia
(35 mg/kg pentobarbital sodium IP) 1 or 2 days before euthanasia.
Cardiac geometry and function were evaluated by 2-dimensional
M-mode echocardiography with a 7-MHz linear transducer. All
measurements, including LV wall thickness and diastolic dimen-
sions, were performed according to the American Society of Echo-
cardiography leading-edge method.11 LV mass was calculated as
previously described.12
Histomorphometric Studies
After isolation of a papillary muscle, the LV was fixed in 10%
buffered formaldehyde for 24 hours and embedded in paraffin. Serial
sections of 4 mm were stained with hematoxylin-eosin for cell
morphometry or picrosirius red (Direct Red 80, Aldrich) for collagen
quantification. Cardiomyocyte cross-sectional area (CSA), collagen
volume fraction (CVF), and the reference area were determined in
each group for an average of 10 micrographs. Because the greatest
degree of fibrosis in the treated groups was confined to the region
below the endocardium, the LV wall was halved into a subendocar-
dial (inner half) and subepicardial (outer half) region, and CVF was
separately quantified in both regions.
Western Blotting
Immunoblot analysis of membrane-enriched fractions was per-
formed with a rabbit polyclonal antibody for NHE-1 (a kind gift from
Dr M. Donowitz, Johns Hopkins University, Baltimore, Md). Detec-
tion of immunoreactive proteins was performed by chemilumines-
cence (Amersham), and signals were quantified by densitometric
analysis. To confirm the specificity of the primary antibody, blots
containing samples of each experimental group were incubated with
secondary antibody alone.
Statistics
Results are expressed as mean6SEM. The Student t test or 1-way
ANOVA followed by the Student-Newman-Keuls test was used
where appropriate. Significance level was set at P,0.05.
An expanded Methods section can be found in an online supple-
ment available at http://www.hypertensionaha.org.
Results
BIIB723 is a new acylguanidine member of the BIIB family
of NHE inhibitors,13 with high oral bioavailability. It displays
selectivity for NHE-1 over NHE-2 of'40-fold and an IC50 of
'30 nmol/L in cardiomyocytes.14 The molecule is closely
related to sabiporide, whose pharmacological properties were
recently reported.15 In 5 of the Iso1BIIB-treated rats, the
serum level of the NHE-1 inhibitor was determined on 3
consecutive days (tenth through the twelfth after the onset of
treatment). The plasma concentration of the inhibitor attained
an average value of 410684 nmol/L. No significant differ-
ence in BW, systolic blood pressure, or heart rate between the
experimental rat groups was observed during the treatment
(Table). Echocardiographic examination showed an increase
in LV internal end-diastolic diameter, anterior end-diastolic
thickness, LV mass, and fractional shortening in the Iso group
(Figure 1). All these effects were cancelled when the NHE-1
inhibitor was combined with Iso. Representative echocardio-
grams of each group are also shown in Figure 1.
At necropsy, HW was increased in the Iso-treated rats, and
this effect was attenuated by NHE-1 blockade. Figure 2 shows
the mean values of HW normalized by BW for each group. The
CSA of LV cardiomyocytes was enlarged in rats treated with Iso
(458611 vs 29464 mm2, n54 each group; P,0.05). This effect
was markedly attenuated by NHE-1 blockade (35765 mm2,
n54; P,0.05 compared with Ctrl and Iso-treated groups).
Representative microphotographs of LV specimens obtained
from each experimental group are shown in Figure 3. The
images illustrate the Iso-induced enlargement of myocyte CSA
and the attenuation of this effect by the NHE-1 inhibitor.
In comparison with Ctrl, myocardial collagen content was
increased in rats treated with Iso. The increase in collagen
was primarily found within the subendocardial region of the
LV wall, in accordance with previous reports (Figure 4).4,16
The increase in CVF in the subendocardium of rats treated
with Iso amounted to 51.263%, compared with 2.260.4% in
Ctrl (n54 each group, P,0.05). Simultaneous inhibition of
NHE-1 activity significantly reduced the increase in suben-
docardial fibrosis to 1361% (n54, P,0.05 vs other groups).
Interestingly, Iso did not induce collagen accumulation in
areas other than the subendocardial region. In the subpericar-
dial region, CVF was 1.960.3 in Ctrl, 2.960.5 in Iso, and
1.960.2% in Iso1BIIB groups (P5NS).
The steady-state value of pHi determined in isolated
papillary muscles bathed with bicarbonate-free (HEPES)-
buffered medium was markedly more alkaline in the Iso than
in the Ctrl group (Figure 5). When the NHE-1 inhibitor
BIIB723 was simultaneously given, this effect of Iso treat-
ment on myocardial pHi was prevented.
Because the bi values were of similar magnitude in all
groups (27.6264.47 in Ctrl, 27.6264.47 in Iso, and
24.3566.11 mmol/L in Iso1BIIB; P5NS), the aforemen-
tioned data strongly suggested that myocardial NHE-1 activ-
ity was enhanced by Iso treatment. To further support this
contention, the effect of acute addition of a widely used
specific inhibitor of NHE-1 activity on myocardial pHi was
assessed in isolated papillary muscles from Iso-treated and
Ctrl rats (Figure 6). When the hypertrophied myocardium of
Iso-treated rats was exposed to HOE 642, the pHi value in the
absence of bicarbonate (HEPES buffer) gradually decreased.
Myocardial pHi also decreased after HOE 642 application in
Ctrl myocardium but to a much lesser extent. The best fit of
the HOE 642–induced decrease in pHi followed an exponential
function that asymptotically approached a similar value in
General Characteristics of the Experimental Groups
Rat Group BW, g SBP, mm Hg HR, bpm
Control (n510)
Before 307.9612.5 121.663.1 39868
After 335.6616.6 122.061.4 38169
Iso (n511)
Before 314.669.5 119.963.6 39568
After 323.3610.5 112.163.3 40062
Iso1BIIB (n58)
Before 328.3613.0 107.666.6 40169
After 335.6614.5 110.663.1 401621
Values are mean6SE; n indicates the number of rats; before and after
indicate values at the onset and at the end of treatment, respectively.
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Iso-treated and Ctrl rats, thus canceling the difference in pHi
between the hypertrophied and normal myocardium (Figure 6B).
In accordance with the functional evidence of enhanced
NHE-1 activity, NHE-1 protein expression was found to be
elevated in the myocardium of Iso-treated rats. In rats that were
simultaneously treated with Iso and the NHE-1 inhibitor, NHE-1
protein expression did not differ from that in the Ctrl group,
indicating that NHE-1 inhibition effectively prevented the Iso-
induced change in antiporter expression (Figure 7). The picture
corresponding to a membrane that was incubated with secondary
antibody alone (first 3 lanes of Figure 7A) did not show any
band, confirming the specificity of the primary antibody.
Discussion
Our results show that Iso-induced myocardial hypertrophy is
accompanied by enhanced NHE-1 activity and expression. In
this regard, Iso-induced CH seems to differ from other models of
CH in which enhanced NHE-1 activity17,18 is not correlated with
an increase in expression of the antiporter,17,19 suggesting a role
for posttranslational mechanisms. Iso-induced effects are atten-
uated by chronic inhibition of the exchanger.
Both in vitro and in vivo studies have established that the
b-adrenergic receptor agonist Iso induces CH.2,20 The renin-
angiotensin system was proposed to be involved in the
development and maintenance of Iso-induced CH.5,6 More
recently, activation of 44- to 42-kDa extracellular signal–
regulated protein kinases through a calcineurin-dependent
mechanism was shown to participate in the development of
Iso-induced CH.7 Our results show that prevention of CH
development by the NHE-1 inhibitor in Iso-treated rats was
accompanied by normalization of NHE-1 expression and
myocardial pHi. The observation that NHE-1 inhibitors exert
antihypertrophic effect is not new.8 NHE-1 inhibition was
shown to regress and prevent CH in hypertensive rats21 and
Figure 1. Echocardiographic assessment of Iso-
induced CH and its attenuation by the NHE-1 in-
hibitor BIIB 723. Mean values (6SEM) of end-dia-
stolic diameter (EDD), fractional shortening (FS),
anterior wall thickness (AWT), and LV mass (LVM)
are shown on the right. Control (n56); Iso, Iso-
treated (n57); Iso1BIIB, combined Iso plus NHE-1
inhibitor treatment (n58). Iso induced an increase
in all of these parameters, which was prevented by
NHE-1 inhibition. *P,0.05 vs Ctrl and Iso1BIIB.
Images on the right show representative
2-dimensional M-mode echocardiograms of each
indicated group.
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mice overexpressing b1-adrenergic receptors,22 as well as to
attenuate the development of cardiomyocyte hypertrophy
after myocardial infarction23 and mechanical stretch.24 To our
knowledge, this is the first demonstration that NHE-1 medi-
ates Iso-induced CH and its prevention by an orally active
NHE-1 inhibitor. The prevention of increased NHE-1 expression
in rats that received Iso combined with BIIB723 seems contra-
dictory with our recent observation that chronic administration
of cariporide to normal rats induced upregulation of the anti-
porter.25 However, it is in accordance with previous studies
reporting the normalization by cariporide of the increased
NHE-1 expression observed in hypertrophied hearts from mice
overexpressing the b1-adrenoreceptors22 and after myocardial
infarction.23 Whether the difference is due to dissimilar re-
sponses of normal hearts and of those exposed to a trophic
stimulus is not evident at present.
The mechanism through which b-receptor activation causes
increased expression of functional NHE-1 protein units is not yet
apparent. Acute Iso stimulation was shown to inhibit NHE-1 and
activate the Na1-independent-Cl2/HCO32 exchanger activities in
cardiac tissue.26,27 Both effects tend to cause intracellular acid-
ification, and one might speculate about a compensatory feed-
back mechanism increasing the expression of NHE-1 protein. It
was shown that chronic intracellular acidosis stimulates NHE-1
expression in renal tissue,28 and isolated cardiomyocytes in-
creased NHE-1 activity in response to chronic external low pH.29
The elevated NHE-1 activity will increase Na1 influx, increasing
its cytosolic concentration, which in turn will lead to a secondary
increase in Ca21i through Na1/Ca21 exchange.30,31 The notion
that the increase in Ca21i is a primary signal for CH is supported
by numerous studies.32–34 The rise in Ca21i activates several
intracellular signaling pathways like protein kinase C35 and
calcium-calmodulin–dependent phosphatase (calcineurin) and
kinases involved in the hypertrophic response. In this regard, a
calcineurin-dependent mechanism was shown to participate in
the development of Iso-induced CH.7 On the other hand, the link
between Na1 influx, activation of protein kinase C-d and e, and
hypertrophy has been previously suggested.36 Alternatively, it
can be argued that increased NHE-1 expression is an epiphe-
nomenon of the trophic effect of b-adrenergic stimulation.
However, the fact that NHE-1 inhibition prevented CH seems to
indicate a cause-effect relation between increased NHE-1 activ-
ity and the induction of CH.
Significant subendocardial fibrosis was noted in the hyper-
trophied hearts of Iso-treated rats, which was attenuated by
combined treatment with the NHE-1 inhibitor. There are
conflicting reports about the presence of fibrosis in Iso-
induced CH. Although some authors found no evidence or
even a decrease in collagen content, an increase in the amount
Figure 2. Mean values (6SEM) of HW normalized by BW (HW/
BW) at necropsy. Groups are labeled as in Figure 1. Iso-induced
CH was reduced by NHE-1 blockade. *P,0.05.
Figure 3. Representative microphotographs showing LV cardio-
myocytes with central nucleus in Ctrl (A), Iso-treated (B), and
Iso1BIIB (C) groups. In Iso-treated rats, enlarged cardiomyo-
cytes with isolated mononuclear infiltrate were observed.
Instead, those rats treated simultaneously with the NHE-1 inhibi-
tor presented cardiomyocytes of smaller size and stromal reac-
tion with capillaries and mononuclear infiltrate. Hematoxylin-
eosin stain; bar5100 mm; magnification 3160.
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of collagen deposition was found in other studies.4,16,37,38 Ben-
jamin et al39 proposed that increased fibrosis after Iso treatment
was predominantly related to myocyte necrosis. Increased cell
necrosis confined to the subendocardial region induced by Iso
treatment has been attributed to the increased susceptibility of
subendocardial cells to ischemia.40 In this regard, the protective
effect of NHE-1 inhibitors to ischemia/reperfusion injury might
have a role in the attenuation of the fibrotic response in hearts of
Iso-treated rats.23 Alternatively, the trophic effect of b-receptor
stimulation might stimulate fibroblast proliferation and collagen
synthesis through an NHE-1–dependent pathway. A similar
antifibrotic action of cariporide was reported in the hypertro-
phied hearts of mice overexpressing b1-adrenoceptors.22
Perspective
CH has been established as 1 of the most powerful predictors
of cardiovascular morbidity and mortality. In the past few
Figure 4. Microphotographs of picrosirius red–stained histologi-
cal LV sections. Few isolated collagen fibers are seen in the LV
from Ctrl rats (A, B), whereas there is increased collagen depo-
sition primarily confined within the subendocardial region of the
ventricular wall in Iso-treated rats (C, D). The Iso1BIIB group
presented a marked reduction in the level of fibrosis (E, F).
Picrosirius red stain; In A–C, bar5400 mm; magnification 325; in
D–F, bar525 mm; magnification 3400.
Figure 5. Myocardial steady pHi value in papillary muscles
bathed with bicarbonate-free (HEPES)-buffered medium. Group
labels are the same as in Figure 1. In Iso-treated rats, myocar-
dial pHi was more alkaline, suggesting increased acid extrusion.
This effect was not observed in rats that were simultaneously
treated with Iso plus the NHE-1 inhibitor BIIB723. *P,0.05
Figure 6. Effect of acute inhibition of NHE-1 activity on the rest-
ing pHi value of hypertrophied and normal myocardium. A, Time
course of the decrease in pHi induced by application of 10
mmol/L HOE 642 (n54 each). Inhibition of NHE-1 activity
induced a larger decrease in pHi in the hypertrophied myocardi-
um, thus cancelling the difference with Ctrl myocardium. B, Bars
show average resting pHi values before HOE 642 (basal) and the
steady pHi value predicted from the exponential fit of the data
shown in A (1HOE). *P,0.05.
Figure 7. Increased NHE-1 protein expression in myocardial tis-
sue from Iso-treated rats and its normalization by treatment with
an NHE-1 inhibitor. A, Western blots from the indicated rat car-
diac membranes. The first 3 lanes correspond to the picture
obtained when the membrane was incubated with the second-
ary antibody alone. B, Mean6SEM NHE-1 protein expression
(arbitrary units) (n53 each); group labels have the same mean-
ing as in Figure 1. *P,0.05.
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years, there has been impressive progress in understanding of
the mechanism(s) of myocardial hypertrophy, and sound
evidence has emerged about the main role played by NHE-1
activity in many, if not all, types of CH. The inhibition of
NHE-1 activity appears to constitute a potential, novel
therapeutic strategy to interfere with the hypertrophic process
independently of load mechanisms.
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